Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 333

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 333
---
, contingent upon the closing of the Business Combination, the Sponsor agreed to forfeit all 4,177,778of its Private Placement Warrants to purchase shares of the Company’s Class A common stock, exercisable at $ 11.50per share (the “Forfeited Private Placement Warrants”), acquired by the Sponsor in March 2021 in connection with the Initial Public Offering. At the closing of the Business Combination, the Forfeited Private Placement Warrants shall be transferred from the Sponsor to the Company for cancellation in exchange for noconsideration and the Company shall retire and cancel all of the Forfeited Private Placement Warrants. NOTE 5. RELATED PARTY TRANSACTIONS Founder Shares In December 2020, the Sponsor paid $ 25,000, or approximately $ 0.004per share, to cover certain offering costs in consideration for 5,750,000Class B common stock, par value $ 0.0001(the “Founder Shares”). In February 2021, the Company effected a stock dividend of 0.2shares for each share of Class B common stock outstanding, resulting in the Sponsor holding an aggregate of 6,900,000Founder Shares (up to an aggregate of 900,000of which were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option is exercised). All shares and associated amounts have been retroactively restated to reflect the stock dividend. As a result of the underwriters’ election to fully exercise their over-allotment option, the 900,000shares were no longer subject to forfeiture. In March 2023, unpaid fees amounting to $ 475, related to reimbursements due to sponsor, have been recorded under accrued expenses. On September 25, 2023, the Sponsor converted all of its Class B common stock on a one-for-one basis into Class A common stock (the “Converted Shares”). The Sponsor will not have any redemption rights in connection with the Converted Shares, and the Converted Shares will be subject to the restrictions on transfer entered into by the Sponsor in connection with the IPO. The Sponsor has agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one yearafter the completion of the initial Business Combination and (B) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction after the initial Business Combination that results in all of its stockholders having the right to exchange their Class A common stock